Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 3
1965 56
1966 68
1967 86
1968 134
1969 110
1970 135
1971 117
1972 167
1973 204
1974 240
1975 326
1976 369
1977 500
1978 537
1979 542
1980 483
1981 627
1982 682
1983 684
1984 855
1985 934
1986 1020
1987 1016
1988 1158
1989 1430
1990 1829
1991 1944
1992 2155
1993 2262
1994 3473
1995 3482
1996 3316
1997 3416
1998 3427
1999 3760
2000 3567
2001 3277
2002 3469
2003 3990
2004 4499
2005 4901
2006 4834
2007 4920
2008 4913
2009 5263
2010 5661
2011 6294
2012 6981
2013 7239
2014 7386
2015 7459
2016 6869
2017 6833
2018 7023
2019 7246
2020 7244
2021 7320
2022 6605
2023 5803
2024 1610

Text availability

Article attribute

Article type

Publication date

Search Results

4,975 results

Results by year

Filters applied: Clinical Trial, in the last 1 year. Clear all
Page 1
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Xu J, et al. JAMA. 2023 Dec 5;330(21):2064-2074. doi: 10.1001/jama.2023.19918. JAMA. 2023. PMID: 38051328 Clinical Trial.
IMPORTANCE: Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few effective treatments are available. ...DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, phase 3 clinical …
IMPORTANCE: Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few eff …
Acupuncture vs Massage for Pain in Patients Living With Advanced Cancer: The IMPACT Randomized Clinical Trial.
Epstein AS, Liou KT, Romero SAD, Baser RE, Wong G, Xiao H, Mo Z, Walker D, MacLeod J, Li Q, Barton-Burke M, Deng GE, Panageas KS, Farrar JT, Mao JJ. Epstein AS, et al. JAMA Netw Open. 2023 Nov 1;6(11):e2342482. doi: 10.1001/jamanetworkopen.2023.42482. JAMA Netw Open. 2023. PMID: 37962891 Free PMC article. Clinical Trial.
IMPORTANCE: Pain is challenging for patients with advanced cancer. While recent guidelines recommend acupuncture and massage for cancer pain, their comparative effectiveness is unknown. OBJECTIVE: To compare the effects of acupuncture and massage on musculoskeletal …
IMPORTANCE: Pain is challenging for patients with advanced cancer. While recent guidelines recommend acupuncture and massage for c …
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
BACKGROUND: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemothera …
BACKGROUND: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a …
Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.
Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Verheij FS, Qin LX, Gollub MJ, Wu AJ, Lee M, Patil S, Hezel AF, Marcet JE, Cataldo PA, Polite BN, Herzig DO, Liska D, Oommen S, Friel CM, Ternent CA, Coveler AL, Hunt SR, Garcia-Aguilar J; OPRA Consortium. Thompson HM, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2350903. doi: 10.1001/jamanetworkopen.2023.50903. JAMA Netw Open. 2024. PMID: 38194231 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This was secondary analysis of the Organ Preservation in Patients with Rectal Adenocarcinoma trial, a phase 2, nonblinded, multicenter, randomized clinical trial. Randomization occurred between April 2014 and March 2020. ...CONCLUS …
DESIGN, SETTING, AND PARTICIPANTS: This was secondary analysis of the Organ Preservation in Patients with Rectal Adenocarcinoma trial, a pha …
Effect of Vitamin D Supplements on Relapse or Death in a p53-Immunoreactive Subgroup With Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial.
Kanno K, Akutsu T, Ohdaira H, Suzuki Y, Urashima M. Kanno K, et al. JAMA Netw Open. 2023 Aug 1;6(8):e2328886. doi: 10.1001/jamanetworkopen.2023.28886. JAMA Netw Open. 2023. PMID: 37606927 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc subgroup analysis of the AMATERASU randomized, double-blind, placebo-controlled clinical trial. This trial included patients at a single university hospital in Japan with digestive tract cancers between J …
DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc subgroup analysis of the AMATERASU randomized, double-blind, placebo-controlled cl …
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Garcia Campelo R, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Fournier B, Dingemans AC, Dziadziuszko R. Remon J, et al. Ann Oncol. 2023 May;34(5):468-476. doi: 10.1016/j.annonc.2023.02.012. Epub 2023 Feb 28. Ann Oncol. 2023. PMID: 36863484 Clinical Trial.
METHODS: APPLE is a randomized, non-comparative, phase II study in patients with common EGFR-mutant, treatment-naive non-small-cell lung cancer including three arms: arm A (osimertinib upfront until RECIST progression, PD), arm B [gefitinib until emergence of circulating t …
METHODS: APPLE is a randomized, non-comparative, phase II study in patients with common EGFR-mutant, treatment-naive non-small-cell lung …
Multitarget Stool RNA Test for Colorectal Cancer Screening.
Barnell EK, Wurtzler EM, La Rocca J, Fitzgerald T, Petrone J, Hao Y, Kang Y, Holmes FL, Lieberman DA. Barnell EK, et al. JAMA. 2023 Nov 14;330(18):1760-1768. doi: 10.1001/jama.2023.22231. JAMA. 2023. PMID: 37870871 Free PMC article. Clinical Trial.
IMPORTANCE: Noninvasive tests for colorectal cancer screening must include sensitive detection of colorectal cancer and precancerous lesions. ...Over the course of 12 months, individuals 45 years and older were enrolled in the clinical trial using the …
IMPORTANCE: Noninvasive tests for colorectal cancer screening must include sensitive detection of colorectal cancer and precan …
Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial.
Kost Y, Deutsch A, Mieczkowska K, Nazarian R, Muskat A, Hosgood HD, Lin J, Daily JP, Ohri N, Kabarriti R, Shinoda K, McLellan BN. Kost Y, et al. JAMA Oncol. 2023 Jul 1;9(7):940-945. doi: 10.1001/jamaoncol.2023.0444. JAMA Oncol. 2023. PMID: 37140904 Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This phase 2/3 randomized clinical trial was conducted from June 2019 to August 2021 with investigator blinding at an urban academic cancer center and enrolled patients with breast cancer or head and neck cancer …
DESIGN, SETTING, AND PARTICIPANTS: This phase 2/3 randomized clinical trial was conducted from June 2019 to August 2021 with i …
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. Thibaudin M, et al. Nat Med. 2023 Aug;29(8):2087-2098. doi: 10.1038/s41591-023-02497-z. Epub 2023 Aug 10. Nat Med. 2023. PMID: 37563240 Free PMC article. Clinical Trial.
Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. ...
Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemothera …
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, Zhou Z, Xu CR, Zheng MY, Li YS, Wang Z, Bai XY, Li AN, Sun YL, Huang J, Lin JX, Ke EE, Xu BF, Lu C, Du Y, Chen Y, Ma R, Wang BH, Cang SD, Wang BC, Chen HJ, Yang JJ, Li Y, Zhou Q, Wu YL. Liu SM, et al. Nat Med. 2023 Aug;29(8):2079-2086. doi: 10.1038/s41591-023-02461-x. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488286 Clinical Trial.
To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC) with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in parallel, a phase 2 adaptive umbrella trial consisting of a criteria-ful …
To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC) with rare genetic mutations in the context …
4,975 results

Searches related to "cancer clinical trial"